新型姜黄素类衍生物的合成与生物学评价

Synthesis and biological evaluation of novel curcuminoid derivatives.

作者信息

Cao Ya-Kun, Li Hui-Jing, Song Zhi-Fang, Li Yang, Huai Qi-Yong

机构信息

Department of Applied Chemistry, Marine College, Shandong University, Weihai 264209, China.

Department of Environmental Engineering, School of Marine Science and Technology, Harbin Institute of Technology, Weihai 264209, China.

出版信息

Molecules. 2014 Oct 13;19(10):16349-72. doi: 10.3390/molecules191016349.

Curcuminoids have been reported to possess multiple bioactivities, such as antioxidant, anticancer and anti-inflammatory properties. Three novel series of curcuminoid derivatives (11a-h, 15a-h and 19a-d) with enhanced bioactivity have been synthesized. Among the synthesized compounds, 11b exhibited the most significant activity with an MIC of 0.5 µM /mL against selected medically important Gram-positive cocci (S. aureus and S. viridans) and Gram-negative bacilli (E. coli and E. cloacae). The derivatives exhibited remarkable results in an antioxidant test with an IC50 2.4- to 9.3-folder smaller than curcuminoids. With respect to antiproliferative activity against Hep-G2, LX-2, SMMC7221 and MDA-MB-231, the derivatives exhibited an effect stronger than curcuminoids with an IC50 ranging from 0.18 to 4.25 µM.

姜黄素类化合物已被报道具有多种生物活性，如抗氧化、抗癌和抗炎特性。已经合成了三个具有增强生物活性的新型姜黄素类衍生物系列（11a-h、15a-h和19a-d）。在合成的化合物中，11b表现出最显著的活性，对选定的医学上重要的革兰氏阳性球菌（金黄色葡萄球菌和绿色链球菌）和革兰氏阴性杆菌（大肠杆菌和阴沟肠杆菌）的最低抑菌浓度为0.5 μM/mL。这些衍生物在抗氧化试验中表现出显著结果，其半数抑制浓度（IC50）比姜黄素类化合物小2.4至9.3倍。关于对肝癌细胞Hep-G2、肝星状细胞LX-2、肝癌细胞SMMC7221和乳腺癌细胞MDA-MB-231的抗增殖活性，这些衍生物表现出比姜黄素类化合物更强的作用，IC50范围为0.18至4.25 μM。